MacroGenics, Inc. (NASDAQ:MGNX) Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its holdings in MacroGenics, Inc. (NASDAQ:MGNX) by 64.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,834 shares of the biopharmaceutical company’s stock after purchasing an additional 15,994 shares during the period. Allspring Global Investments Holdings LLC owned 0.07% of MacroGenics worth $393,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in MacroGenics by 7.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,337 shares of the biopharmaceutical company’s stock valued at $475,000 after purchasing an additional 3,319 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of MacroGenics by 349.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,174 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 5,577 shares during the period. SG Americas Securities LLC boosted its position in MacroGenics by 36.9% during the fourth quarter. SG Americas Securities LLC now owns 28,589 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 7,712 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in MacroGenics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 30,085 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 7,629 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in MacroGenics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,414,924 shares of the biopharmaceutical company’s stock worth $20,574,000 after acquiring an additional 36,396 shares during the period. Hedge funds and other institutional investors own 96.89% of the company’s stock.

Insider Activity at MacroGenics

In related news, SVP Ezio Bonvini sold 13,316 shares of MacroGenics stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $15.00, for a total transaction of $199,740.00. Following the sale, the senior vice president now owns 74,668 shares of the company’s stock, valued at approximately $1,120,020. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Ezio Bonvini sold 13,316 shares of MacroGenics stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $15.00, for a total value of $199,740.00. Following the completion of the sale, the senior vice president now owns 74,668 shares in the company, valued at $1,120,020. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Jeffrey Stuart Peters sold 16,124 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $17.22, for a total transaction of $277,655.28. Following the completion of the sale, the vice president now owns 8,895 shares in the company, valued at approximately $153,171.90. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 80,835 shares of company stock worth $1,276,588. 11.30% of the stock is currently owned by company insiders.

MacroGenics Trading Up 1.3 %

Shares of MGNX stock opened at $14.56 on Friday. The company has a market cap of $910.87 million, a PE ratio of -91.00 and a beta of 2.09. The company’s fifty day simple moving average is $16.73 and its 200-day simple moving average is $11.91. MacroGenics, Inc. has a 52 week low of $4.29 and a 52 week high of $21.88.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.49). The company had revenue of $10.72 million during the quarter, compared to analysts’ expectations of $25.70 million. MacroGenics had a negative net margin of 15.42% and a negative return on equity of 88.49%. During the same period last year, the business earned $0.21 earnings per share. Equities research analysts expect that MacroGenics, Inc. will post -2.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. B. Riley started coverage on MacroGenics in a research note on Friday. They set a “buy” rating and a $25.00 price target on the stock. Barclays upped their price target on shares of MacroGenics from $12.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. TheStreet lowered shares of MacroGenics from a “c” rating to a “d” rating in a report on Thursday, March 7th. TD Cowen upgraded MacroGenics from a “hold” rating to a “buy” rating in a report on Tuesday, April 9th. Finally, JMP Securities reaffirmed a “market outperform” rating on shares of MacroGenics in a research report on Thursday, April 4th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.00.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.